Last reviewed · How we verify
Omnicef Cap.
Omnicef (cefdinir) is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Omnicef (cefdinir) is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Community-acquired pneumonia, Acute exacerbation of chronic bronchitis, Acute maxillary sinusitis.
At a glance
| Generic name | Omnicef Cap. |
|---|---|
| Also known as | cefdinir |
| Sponsor | Korea United Pharm. Inc. |
| Drug class | Third-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefdinir works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against common respiratory and skin infections. The drug is bactericidal and is typically used for oral treatment of mild to moderate infections.
Approved indications
- Community-acquired pneumonia
- Acute exacerbation of chronic bronchitis
- Acute maxillary sinusitis
- Pharyngitis/tonsillitis
- Uncomplicated skin and skin structure infections
- Urinary tract infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Vaginal yeast infection
- Abdominal pain
- Rash
Key clinical trials
- Cefdinir Capsules 300 mg, Fasting (PHASE1)
- Cefdinir Capsules 300 mg, Non-fasting (PHASE1)
- Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children (PHASE4)
- Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis (PHASE4)
- The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis (PHASE2, PHASE3)
- Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults (PHASE4)
- To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions (PHASE1)
- To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omnicef Cap. CI brief — competitive landscape report
- Omnicef Cap. updates RSS · CI watch RSS
- Korea United Pharm. Inc. portfolio CI